文献速递淋巴瘤

PDL1/PDL2基因高表达与原发纵隔大B细胞淋巴瘤较差结局相关

High PDL1/PDL2 gene expression correlates with worse outcome in primary mediastinal large B-cell lymphoma.
PubMed 文献 · Blood Adv · 2023-01-01

该回顾性多中心队列纳入120例接受一线免疫化疗的原发纵隔大B细胞淋巴瘤患者,基因表达谱分析显示仅PDL1和PDL2表达与生存相关;PDL1高/PDL2高表达者占30.8%,多因素分析中为不良预后的独立因素,并在40例独立队列中验证其与较差无进展生存相关。

要点

  • 在137个检测标志物中,仅PDL1和PDL2基因表达显示预后影响。
  • PDL1高/PDL2高表达者占30.8%,其基线临床特征与其他患者相似。
  • PDL1高/PDL2高表达在多因素分析中为无进展生存和总生存的不良独立预后因素。

核心结论

  • PDL1/PDL2基因高表达定义了一个具有强免疫豁免且标准化疗预后较差的人群,可能从一线检查点抑制剂治疗中获益。

研究设计与样本

  • 回顾性多中心队列,对接受一线免疫化疗的患者进行分子特征分析,基因表达谱数据可分析者120例。
  • 在40例独立队列中验证结果。

主要发现

  • 患者中位年龄34岁(范围18-67岁);女性58.3%;乳酸脱氢酶升高82.5%;东部肿瘤协作组体能状态评分0-1分85.7%;Ann Arbor分期I/II期55%;国际预后指数评分1-2分64.4%;中位代谢肿瘤体积290.4 cm³(范围15.7-1147.5 cm³)。
  • 在137个检测标志物中,仅PDL1和PDL2表达显示预后影响;PDL1和PDL2基因均高表达者37例(30.8%)。
  • 单因素分析中,PDL1高/PDL2高状态与较差无进展生存相关(风险比[HR] 4.292)和总生存相关(HR 8.24)。
  • 多因素分析中,PDL1高/PDL2高状态为不良结局的独立预后因素(无进展生存:HR 5.22;总生存:HR 10.368)。
  • 在40例独立队列中验证,确认PDL1高/PDL2高状态与较差无进展生存显著相关(HR 6.11)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Primary mediastinal B-cell lymphoma (PMBL) is an uncommon entity of aggressive B-cell lymphoma with an unusually good prognosis, except for 10-15% of chemotherapy-refractory cases. To identify earlier these higher risk patients, we performed molecular characterization of a retrospective multicenter cohort of patients treated with firstline immunochemotherapy. The traits of the patients with gene-expression profiling data (n = 120) were as follows: median age of 34 years (range, 18-67 years); female sex, 58.3%; elevated lactate dehydrogenase, 82.5%; Eastern Cooperative Oncology Group performance status score of 0 to 1, 85.7%; Ann Arbor stage I/II, 55%; International Prognostic Index score of 1 to 2, 64.4%; and median metabolic tumor volume, 290.4 cm3 (range, 15.7-1147.5 cm3). Among all 137 markers tested for correlation with survival data, only programmed death-ligand (PDL) 1 and PDL2 expression showed a prognostic impact. Overall, both PDL1 and PDL2 genes were highly expressed in 37 patients (30.8%; PDL1high/PDL2high). The baseline clinical characteristics of patients with PDL1high/PDL2high were similar to those of other patients. In univariate analysis, PDL1high/PDL2high status was associated with poor progression-free survival (PFS) (hazard ratio [HR], 4.292) and overall survival (OS; HR, 8.24). In multivariate analysis, PDL1high/PDL2high status was an independent prognostic factor of adverse outcomes (PFS: HR, 5.22; OS: HR, 10.368). We validated these results in an independent cohort of 40 patients and confirmed the significant association between PDL1high/PDL2high status and inferior PFS (HR, 6.11). High PDL1/PDL2 gene expression defines a population with strong immune privilege and poorer outcomes from standard chemotherapy who might benefit from firstline checkpoint inhibitor therapy.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Camus V, Viailly PJ, Drieux F, et al. High PDL1/PDL2 gene expression correlates with worse outcome in primary mediastinal large B-cell lymphoma. Blood Adv. 2023. PMID: 37862676. doi:10.1182/bloodadvances.2023011169

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。